My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AtriCure, Inc. - Common Stock (NQ:ATRC)

27.75 -0.46 (-1.63%)

Streaming Delayed Price Updated: 9:42 AM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

AtriCure Inc (NASDAQ:ATRC) Stock Surges on Q4 2025 Earnings Beat and Profitability Milestone ↗

February 17, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching? ↗

March 18, 2026

This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns.

Via The Motley Fool

Topics Derivatives Regulatory Compliance

AtriCure to Participate in the Citizens Life Sciences Conference

February 24, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure (ATRC) Q4 2025 Earnings Call Transcript ↗

February 17, 2026

AtriCure (ATRC) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results

February 17, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results

January 27, 2026

From AtriCure, Inc.

Via Business Wire

AI Diagnostics: The End of the High-Cost Imaging Era

January 16, 2026

Issued on behalf of VentriPoint Diagnostics Ltd.

From Equity Insider

Via GlobeNewswire

What's going on in today's pre-market session ↗

January 15, 2026

Via Chartmill

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026

January 12, 2026

From AtriCure, Inc.

Via Business Wire

AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference

December 17, 2025

From AtriCure, Inc.

Via Business Wire

AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

December 11, 2025

From AtriCure, Inc.

Via Business Wire

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares? ↗

November 29, 2025

This cardiac device maker focused on atrial fibrillation saw a notable insider sale following a year of flat share performance.

Via The Motley Fool

Topics Regulatory Compliance

AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 18, 2025

From AtriCure, Inc.

Via Business Wire

AtriCure (ATRC) Q3 2025 Earnings Call Transcript ↗

October 30, 2025

AtriCure (ATRC) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

AtriCure Inc (NASDAQ:ATRC) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Outlook ↗

October 29, 2025

AtriCure's Q3 2025 earnings beat expectations with a narrowed loss and strong revenue growth. The medical device firm also raised its full-year financial outlook.

Via Chartmill

Topics Earnings

AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

October 29, 2025

From AtriCure, Inc.

Via Business Wire

AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial

October 28, 2025

From AtriCure, Inc.

Via Business Wire

AtriCure to Participate in Upcoming Investor Conferences

October 27, 2025

From AtriCure, Inc.

Via Business Wire

AtriCure to Announce Third Quarter 2025 Financial Results

October 08, 2025

From AtriCure, Inc.

Via Business Wire

AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation

September 09, 2025

From AtriCure, Inc.

Via Business Wire

AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference

August 20, 2025

From AtriCure, Inc.

Via Business Wire

AtriCure (ATRC) Q2 2025 Earnings Call Transcript ↗

August 06, 2025

Via The Motley Fool

Topics Earnings

AtriCure (ATRC) Q2 Revenue Jumps 17% ↗

July 30, 2025

Via The Motley Fool

Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket ↗

July 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 29, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.